Annexon (ANNX) Jefferies Global Healthcare Conference 2026 summary

Strategic focus and differentiation

• Pioneering upstream C1q inhibition for neuroinflammatory diseases, aiming for broader and more complete protection than downstream complement approaches.

• Lead programs target Guillain-Barré syndrome (GBS) and geographic atrophy (GA), both in late-stage development with strong efficacy signals.

• GA program uniquely demonstrates significant vision and photoreceptor preservation, unlike competitors.

• Three major clinical catalysts expected in 2024: GBS FORWARD study data, ANX1502 small molecule data, and GA phase III data.

• Corporate strategy includes seeking non-dilutive funding and maintaining a wholly owned platform.

Clinical development and milestones

• GBS: Phase III pivotal program successful; EU approval filed, US BLA planned after FORWARD study data release (5–10 Western patients).

• GA: Phase III data readout expected in Q4 2024, aiming to replicate phase II results showing 73% risk reduction in 15-letter vision loss.

• ANX1502: First-in-class oral small molecule targeting neuromuscular diseases, with initial data (up to 6 patients) expected before GA data.

• All three programs have key data readouts or milestones in 2024.

• GA phase III study is event-driven, with primary endpoint of confirmed 15-letter loss at two visits; study on track for 15-month readout.

Regulatory and trial design

• GA phase III: Single protocol for EU (659 patients), two sub-studies for US per FDA guidance, both powered >90%.

• Enrichment strategies include excluding patients with very poor vision and focusing on those with foveal involvement to increase event rates.

• If only one US sub-study meets endpoint, data from both will be considered for regulatory submission.

• RPE lesion growth is tracked for investor interest but not required by regulators; photoreceptor protection is the key efficacy driver.

• Safety profile in GA phase II showed no retinal vasculitis or increased choroidal neovascularization; phase III expected to replicate this.